Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Tacrolimus (Prograf) is a medication that is commonly used in patients who receive a kidney
transplant. It is considered to be one of the most important medications that prevent
rejection of the transplant kidney by suppressing the immune system. Although tacrolimus is
good at preventing rejection, it does have some unwanted side effects. These side effects
include high blood pressure, increase in blood sugar, headache, and tremor. In addition,
tacrolimus causes some damage to the transplant kidney over time, by causing healthy tissue
to turn into scar tissue that does not function as well as healthy tissue. Therefore, kidney
function may be reduced over time. In the first three months after kidney transplant, Prograf
levels are kept between 8 to 10 ng/mL. This study will compare two groups of patients that
will both have their tacrolimus dose reduced slowly over three months to prevent rejection
while decreasing the risk of causing toxic effects to the kidney. One group will have their
Prograf levels kept between 6 and 8 ng/mL, while the second group will have their levels kept
between 3 and 5 ng/mL. We will then compare the two groups to see if there are any
differences in their kidney function over time.